Matches in Wikidata for { <http://www.wikidata.org/entity/Q91473210> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q91473210 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91473210 description "scientific article published on 26 November 2019" @default.
- Q91473210 description "wetenschappelijk artikel" @default.
- Q91473210 description "наукова стаття, опублікована 26 листопада 2019" @default.
- Q91473210 description "գիտական հոդված հրատարակված 2019 թվականի նոյեմբերի 26-ին" @default.
- Q91473210 name "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 name "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 type Item @default.
- Q91473210 label "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 label "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 prefLabel "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 prefLabel "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 P1433 Q91473210-27C7009B-5ADC-42B4-8259-EA86E330AF6D @default.
- Q91473210 P1476 Q91473210-11C37238-0BF6-4198-9936-7548C2E97C95 @default.
- Q91473210 P2093 Q91473210-0313E0C3-17AB-493E-8C30-E4CD045B4F3E @default.
- Q91473210 P2093 Q91473210-0DB7CB78-D1C2-47D6-9B8A-590261A9288C @default.
- Q91473210 P2093 Q91473210-0E23A5F2-CE8D-4902-9A2D-E8F215D6CB85 @default.
- Q91473210 P2093 Q91473210-1DA96264-E10E-4597-B4CA-647B6B04B4CC @default.
- Q91473210 P2093 Q91473210-223FAEC9-943F-41C4-9848-FDEE1D0597DD @default.
- Q91473210 P2093 Q91473210-316FBA84-CF30-434D-B2A2-5FEE5AFDFE7B @default.
- Q91473210 P2093 Q91473210-3873F9F5-410D-4F9C-A1CE-F8598ADC0B89 @default.
- Q91473210 P2093 Q91473210-735F7588-06A6-4F5D-8EFB-881470CA6DE5 @default.
- Q91473210 P2093 Q91473210-76CAB6AE-A396-4E0C-BED3-1A0BBCA6B795 @default.
- Q91473210 P2093 Q91473210-80756387-B1B7-44A8-AC5F-DA8BDDF19EE5 @default.
- Q91473210 P2093 Q91473210-C1746E11-9877-4ADB-AAF3-101FC36ED350 @default.
- Q91473210 P2093 Q91473210-C2F110C4-6233-4F3B-A653-928C5369F09F @default.
- Q91473210 P2093 Q91473210-D020759A-0223-4072-9B4C-23885662814E @default.
- Q91473210 P2093 Q91473210-F38F5C04-A966-4B17-BEAF-1D9745DAD2CC @default.
- Q91473210 P2093 Q91473210-FF24E495-AE8D-44F5-A826-12D1387F84CC @default.
- Q91473210 P304 Q91473210-7C680387-C7CF-4414-AEDB-34447D8ACE51 @default.
- Q91473210 P31 Q91473210-4D9985B9-EE88-4F43-B026-08F584B4EF5D @default.
- Q91473210 P356 Q91473210-40A8F9DB-D0AF-4B2F-999F-480765110A6F @default.
- Q91473210 P433 Q91473210-63255F7D-D6F8-4D06-829C-8159342E488B @default.
- Q91473210 P478 Q91473210-8B7D63DD-00C9-4273-8C8D-E9B588EE9DF6 @default.
- Q91473210 P50 Q91473210-3C633DEC-BD4F-4F6F-BAD3-6B72D8EC5022 @default.
- Q91473210 P577 Q91473210-5B040B1E-2477-4895-9C8D-799A26D56709 @default.
- Q91473210 P698 Q91473210-02FED7F5-50EF-475F-B08F-6E0309A3A66C @default.
- Q91473210 P921 Q91473210-3893D3B2-EECC-4C8C-8418-5BE443EF0043 @default.
- Q91473210 P356 1078-0432.CCR-19-2152 @default.
- Q91473210 P698 31772119 @default.
- Q91473210 P1433 Q332253 @default.
- Q91473210 P1476 "Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study" @default.
- Q91473210 P2093 "Aaron Zhan" @default.
- Q91473210 P2093 "Basem M William" @default.
- Q91473210 P2093 "Charalambos Andreadis" @default.
- Q91473210 P2093 "Chen-Yen Yang" @default.
- Q91473210 P2093 "Erika Cavallone" @default.
- Q91473210 P2093 "Frank McCormick" @default.
- Q91473210 P2093 "Jonathan E Brammer" @default.
- Q91473210 P2093 "Khoan Vu" @default.
- Q91473210 P2093 "Laura Pincus" @default.
- Q91473210 P2093 "Lawrence K Kaplan" @default.
- Q91473210 P2093 "Matthew J Wieduwilt" @default.
- Q91473210 P2093 "Pamela Heeter" @default.
- Q91473210 P2093 "Pierluigi Porcu" @default.
- Q91473210 P2093 "Wade Berry" @default.
- Q91473210 P2093 "Weiyun Z Ai" @default.
- Q91473210 P304 "1000-1008" @default.
- Q91473210 P31 Q13442814 @default.
- Q91473210 P356 "10.1158/1078-0432.CCR-19-2152" @default.
- Q91473210 P433 "5" @default.
- Q91473210 P478 "26" @default.
- Q91473210 P50 Q87812561 @default.
- Q91473210 P577 "2019-11-26T00:00:00Z" @default.
- Q91473210 P698 "31772119" @default.
- Q91473210 P921 Q18936 @default.